Form 4: ARTL CEO Converts Notes to Warrants, New Debt

ARTELO Biosciences CEO Gregory Gorgas converted a portion of a convertible promissory note into warrants and reinvested the remainder into a new convertible note and additional warrants.

Summary

• Gregory D. Gorgas, who serves as Director, President, CEO, Treasurer, and Secretary of ARTELO Biosciences, Inc. (ARTL), engaged in a series of transactions on October 28, 2025.
• A portion of a convertible promissory note, originally issued to Mr. Gorgas on May 1, 2025 (the "May Note"), was automatically converted into a warrant (the "$6.24 Warrant") to purchase 9,586 shares of the Issuer's common stock at an exercise price of $6.24 per share.
• The remaining portion of the May Note was converted and reinvested, along with other investors, into a new convertible note (the "October Note") with a principal amount of $27,710, and an additional warrant (the "$3.40 Warrant") to purchase 17,952 shares of common stock at an exercise price of $3.40 per share.
• The October Note grants Mr. Gorgas the right to convert its principal amount, plus accrued and unpaid interest, into shares of the Issuer's Common Stock at any time prior to its full payment.
• Both the $6.24 Warrant and the $3.40 Warrant became exercisable on October 28, 2025, and are set to expire on October 28, 2030. The October Note is convertible from October 28, 2025, and expires on April 28, 2026.

Sentiment

Score: 6

Explanation: The insider's continued investment and restructuring of debt into equity-linked instruments can be viewed positively as a sign of confidence. However, the potential for future dilution from warrants and convertible notes introduces a moderate negative aspect.

Positives

• Continued investment by a key insider (CEO Gregory D. Gorgas) demonstrates ongoing confidence in the company's future prospects.
• The restructuring of existing debt (May Note) into equity-linked instruments (warrants) and a new convertible note indicates a strategic management of the insider's investment, potentially aligning interests more closely with shareholders.

Negatives

• The issuance of warrants and convertible notes creates potential for future dilution of existing shareholders if these instruments are exercised or converted into common stock, increasing the total number of outstanding shares.

Risks

• Potential future dilution of existing shareholders if the warrants are exercised or the convertible note is converted into common stock.
• The presence of convertible debt and warrants can create an overhang on the stock, which may exert downward pressure on the share price.

Future Outlook

The filing indicates that the October Note is convertible into shares of the Issuer's Common Stock at any time prior to its payment in full, suggesting potential future equity conversion by the reporting person.

Management Comments

• Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the 'May Note'), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ('Common Stock') (the '$6.24 Warrant').
• On October 28, 2025, the Issuer entered into a Subscription Agreement (the 'Subscription Agreement') pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the 'October Note'), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the '$3.40 Warrant').
• At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock.

Industry Context

NA

Related Party Transactions

• The transactions detailed involve Gregory D. Gorgas, a Director, President, CEO, Treasurer, and Secretary of ARTELO Biosciences, Inc., making them related party transactions.
• Specifically, the conversion of a convertible promissory note (May Note) and the subsequent reinvestment into new warrants and a new convertible note (October Note) involve the company and its CEO.

Stakeholder Impact

• Shareholders: Potential for future dilution if warrants are exercised or the convertible note is converted, which could impact per-share value. However, continued insider investment may be seen as a positive signal of confidence.
• Creditors: The conversion of debt into equity-linked instruments could reduce the company's immediate debt burden, potentially improving its balance sheet from a debt perspective.

Next Steps

• Potential exercise of the $6.24 Warrant and $3.40 Warrant by Gregory D. Gorgas prior to their expiration on October 28, 2030.
• Potential conversion of the October Note into shares of Common Stock by Gregory D. Gorgas prior to its expiration on April 28, 2026.

Key Dates

Recommendation

The filing details a pre-planned restructuring of an insider's investment, converting existing debt into warrants and a new convertible note. While continued insider involvement is generally positive, the potential for future dilution from these instruments warrants a cautious 'hold' stance. There are no immediate catalysts for significant price movement, and the implications of the conversions are already largely factored into the company's capital structure.

Keywords

ARTELO Biosciences, ARTL, Gregory D. Gorgas, Form 4, Insider Transaction, Convertible Note, Warrant, Equity Conversion, CEO, Director, Dilution, SEC Filing